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OBJECTIVE: To evaluate the cost-effectiveness of atypical anti-
psychotic treatment sequences for the management of stable
schizophrenia in the UK. METHODS: A Markov model was
developed to assess the cost per quality adjusted life year (QALY)
gained from 12 alternative treatment sequences each containing
two atypical antipsychotics (aripiprazole (ARI), olanzapine
(OLZ), quetiapine (QTP), and risperidone (RSP)), followed by
clozapine. The main model parameters were populated with data
from the CATIE study, which provides a direct comparison of the
effectiveness of OLZ, QTP and RSP, a recent trial of ARI com-
pared with OLZ in the long-term treatment of schizophrenia,
and a recent study of diabetes incidence in atypical treated
patients. Patients enter the model with stable schizophrenia. On
each treatment patients may relapse, discontinue, or continue
and experience adverse events (extrapyramidal symptoms,
weight gain, hyperprolactinemia), or develop diabetes. Popula-
tion mortality was adjusted for schizophrenia and diabetes.
Utility decrements applied to stable schizophrenia, relapse, dia-
betes, and treatment related adverse events were taken from a
direct UK utility elicitation study. Dosing for OLZ, QTP, and
RSP was based on CATIE. ARI is ﬂat priced within the ranges of
5–15 mg and 20–30 mg; we assumed a simple average of these
doses. Resource use and unit costs were taken from published
sources. A time horizon of 10 years was adopted. RESULTS: ARI
followed by RSP produced the greatest number of QALYs, an
additional 0.03 compared to RSP followed by OLZ, at an incre-
mental cost of £222 (incremental cost per QALY: £7942). ARI
followed by RSP had the greatest probability among evaluated
sequences of being cost effective at a threshold of £10,000 per
QALY or higher. CONCLUSION: First-line atypical treatment
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OBJECTIVE: ADHD is the most common behavioral disorder of
childhood and adolescence in the US and Europe. The NIMH-
initiated MTA Study still is the clinical landmark trial in the ﬁeld,
including 579 children age 7–9.9 years with ADHD (DSM-IV),
who were randomly assigned to 14 months of medication man-
agement (MedMgt), intense behavioral treatment (Beh), both
combined (Comb), or community care (CC). All MTA treatment
strategies were clinically effective. The intensity of the MTA Beh
strategy, designed to maximize clinical effectiveness, resulted in
disappointing incremental cost-effectiveness ratios, being invari-
ably dominated by MedMgt. Applying current cost-effectiveness
benchmarks, this study aimed to estimate themaximum allowable
cost (MAC) of better-targeted psychosocial interventions, assum-
ing they replicate the effectiveness achieved in the MTA Study.
METHODS: For costing, medical resource utilization data from
the MTA, excluding its research component, were combined with
unit costs (year 2005) from a societal and from a third-party
payer’s perspective for the United States as well as for Germany,
Netherlands, Sweden, and UK. Treatment response was deﬁned as
normalization of core symptoms. QALYs were estimated using
utility weights derived from expert and parent-proxy-ratings.
RESULTS: MACs for Beh were determined (a) for ADHD and
for subgroups (b) with “pure” ADHD (without co-morbidity,
n = 184) and (c) hyperkinetic disorder (HKD, with or without
conduct disorder, n = 145), assuming (1) Beh meeting the ICERs
of MedMgt (versus CC), or meeting an ICER threshold (when
added to MedMgt) of (2) €50,000 or (3) €100,000 per QALY.
MACs (US) were (1) €1130, (2) €2470, and (3) €3720 (exchange
rate [2005]: USD$1 = €0.85). Estimates for Germany and Neth-
erlands were broadly similar, whereas British and Swedish esti-
mates were substantially higher, up to (1) €2250, (2) €3600, and
(3) €5420. CONCLUSION: Despite limitations, these estimates
may assist clinical study planners aiming at showing acceptable
cost-effectiveness of psychosocial treatment strategies for ADHD.
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OBJECTIVE: To assess the cost-effectiveness of olanzapine orally
dissolving tablets (ODT) and olanzapine standard oral tablets
(SOT) during the usual treatment of schizophrenia patients from
a U.S. health care perspective. The model also compared olan-
zapine ODT with other antipsychotics in SOT and ODT formu-
lations. METHODS: Published medical literature, unpublished
data, and a clinical expert panel were used to populate a one-year
micro-simulation model comparing olanzapine ODT with olan-
zapine SOT, and with other antipsychotics in SOT (risperidone,
quetiapine, ziprasidone, aripiprazole and perphenazine) and
ODT formulations (risperidone and aripiprazole). The model
captures clinical and cost parameters including adherence levels,
treatment discontinuation by reason, relapse with and without
inpatient hospitalization, quality-adjusted life years (QALYs),
treatment-emergent adverse events, health care resource utiliza-
tion and associated costs. Key results were annual direct cost per
treatment and incremental cost-effectiveness values per one inpa-
tient relapse avoided and per one QALY gained. RESULTS:
Based on model projections, olanzapine ODT therapy was
slightly more costly ($9674 vs. $9602) but more effective in
terms of a lower hospitalization rate (14% vs. 16%) and better
QALY (0.78 vs. 0.75) than olanzapine SOT therapy, with favor-
able incremental cost per inpatient relapse avoided ($2157) and
QALY gained ($2454). Olanzapine ODT was more cost-effective
than olanzapine SOT and also more cost-effective compared to
other comparators. CONCLUSION: The utilization of olanzap-
ine ODT for the treatment of schizophrenia is predicted in this
model to be more cost-effective than olanzapine in standard oral
tablets and more cost-effective than other comparators in either
orally dissolving tablet or standard tablet formulations.
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